Martin VanTrieste's guest appearances

Martin VanTrieste

Pharmacy Podcast Network

Hospitals In Focus

A Second Opinion with Senator Bill Frist, M.D.

SenioRX Radio

Unscripted

Jon Perlin

David Dill

Jeff Goldsmith

Jonathan Perlin

Larry Levitt

Marty Makary

Eric Topol

Sam Quinones

Jay Butler

Leana Wen

Johns Hopkins

Avik Roy

Sam Hazen

Karen Johnson

David Williams

OwlTail

Martin Van Trieste, BPharm, is the President and CEO of Civica Rx, which is a non-profit company whose mission is to ensure that essential generic medications are accessible and affordable. Civica Rx has partnered with health systems to reduce drug shortages and recently announced they will begin manufacturing insulin for release in 2024 that will cost no more than $30 per vial and no more than $55/box of 5 pen cartridges. Martin has been named one of the 100 most influential people in healthcare!https://civicarx.org 

Martin Van Trieste, BPharm, is the President and CEO of Civica Rx, which is a non-profit company whose mission is to ensure that essential generic medications are accessible and affordable.  Civica Rx has partnered with health systems to reduce drug shortages and recently announced they will begin manufacturing insulin for release in 2024 that will cost no more than $30 per vial and no more than $55/box of 5 pen cartridges. Martin has been named one of the 100 most influential people in healthcare!<a href="https://civicarx.org/" rel="nofollow" target="_blank">https://civicarx.org</a>

32. Martin VanTrieste - President and CEO, Civica Rx

Martin VanTrieste is the President and CEO of Civica Rx, a groundbreaking, non-profit pharmaceutical company that’s innovatively working to address our nation’s generic drug shortages.  For years, our domestic drug manufacturing and supply chains have eroded, resulting in shortages of anesthetics, antibiotics, cancer drugs, even sterile IV fluids necessary for delivering nearly every drug used in a surgical setting.  Martin, who was recently named one of Modern Healthcare’s 100 Most Influential People in Healthcare, is working at the cutting edge with his team at Civica to make drug shortages a thing of the past. Visit A Second Opinion's website here: https://asecondopinionpodcast.com/ Engage with us on social media at: Facebook Twitter Instagram

Martin VanTrieste is the President and CEO of Civica Rx, a groundbreaking, non-profit pharmaceutical company that’s innovatively working to address our nation’s generic drug shortages.  For years, our domestic drug manufacturing and supply chains have eroded, resulting in shortages of anesthetics, antibiotics, cancer drugs, even sterile IV fluids necessary for delivering nearly every drug used in a surgical setting.  Martin, who was recently named one of Modern Healthcare’s 100 Most Influential People in Healthcare, is working at the cutting edge with his team at Civica to make drug shortages a thing of the past. Visit A Second Opinion's website here: <a href="https://asecondopinionpodcast.com/" rel="nofollow" target="_blank">https://asecondopinionpodcast.com/</a> Engage with us on social media at: <a href="https://www.facebook.com/ASOPodcast" rel="nofollow" target="_blank">Facebook</a> <a href="https://twitter.com/ASOpodcast" rel="nofollow" target="_blank">Twitter</a> <a href="https://www.instagram.com/asopodcast/" rel="nofollow" target="_blank">Instagram</a>

70 - Martin VanTrieste, CEO of Civica Rx, on ending generic drug shortages

Continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and putting strains on hospital budgets and operations. That’s why hospitals and health systems have gathered to create Civica Rx, a not-for-profit generic drug company that is disrupting the pharmaceutical market. Chip spoke with Martin VanTrieste, Civica’s President &amp; CEO about why and how the company was formed, the success it is enjoying so far, and if other drug companies will follow its lead. EPISODE UPDATE, Since our recording VIZIENT has announced it will collaborate with Civica to help reduce chronic drug shortages by providing insights into purchasing patterns and provider needs. Vizient will apply its expertise in analytics and data capabilities, helping Civica anticipate gaps in drug availability and affordability.  In response to Vizient’s commitment, Civica’s VanTrieste said, “The more people collaborating to solve the nation’s drug shortage problem the better…we applaud Vizient for prioritizing hospital patients by taking action to help them have timely access to the treatments they desperately need on a day-to-day basis.” 

Continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and putting strains on hospital budgets and operations. That’s why hospitals and health systems have gathered to create Civica Rx, a not-for-profit generic drug company that is disrupting the pharmaceutical market. Chip spoke with Martin VanTrieste, Civica’s President &amp; CEO about why and how the company was formed, the success it is enjoying so far, and if other drug companies will follow its lead. EPISODE UPDATE, Since our recording VIZIENT has announced it will collaborate with Civica to help reduce chronic drug shortages by providing insights into purchasing patterns and provider needs. Vizient will apply its expertise in analytics and data capabilities, helping Civica anticipate gaps in drug availability and affordability. In response to Vizient’s commitment, Civica’s VanTrieste said, “The more people collaborating to solve the nation’s drug shortage problem the better…we applaud Vizient for prioritizing hospital patients by taking action to help them have timely access to the treatments they desperately need on a day-to-day basis.”

Disrupting the Drug Market with Martin VanTrieste

Show Notes: Martin VanTrieste, President &amp; Chief Executive Officer, Civica - Martin VanTrieste brings over 35 years in the pharmaceutical industry – focusing on manufacturing and quality. He was ranked #2 on the 2018 Medicine Maker Power List of Industry Influencers. Martin VanTrieste was the Chairman of the Parenteral Drug Association (PDA) Board of Directors. The PDA represents over 10,000 members, and is the leading global facilitator of scientifically sound, practical technical information, quality systems and expertise to advance Pharmaceutical / biopharmaceutical manufacturing science and regulation so members can better serve patients. He recently retired as the senior vice president of quality at Amgen. He was responsible for quality assurance, quality control, compliance, operational excellence, environment, health and safety along with training at Amgen. Prior to joining Amgen, VanTrieste was with Bayer Healthcare’s Biological ProductsDivision as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division. While at Abbott, VanTrieste held various positions in Quality, Operations, and Research and Development. He started his career at Abbott in 1983 after obtaining his Pharmacy degree from Temple University School of Pharmacy. He is the founder of Rx-360 and first Chairman of the Board of Directors. Rx-360 is a nonprofit international supply chain organization that enhances patient safety by increasing the security and quality in the biopharmaceutical supply chain. VanTrieste has been actively involved with various professional and trade organizations, including, United States Pharmacopeia (USP), Pharmaceutical Quality Research Institute (PQRI), Pharmaceutical Research and Manufactures of America (PhRMA), and AdvaMed. PharmaVoice in 2012 named VanTrieste as one of the 100 most inspiring people inthe pharmaceutical industry, calling him “a man with a mission”. The MedicineMaker in 2016, 2017 and 2018 named him one of the most influential people in the world of drug development and manufacture saying, “he is known throughoutindustry for his work on advancing quality assurance and helping to ensure a more reliable supply of high-quality medicines.”    Civica Webpage: https://civicarx.org/    ASCP's call for proposals page - share your expertise with our members in 2019!  https://www.ascp.com/page/callforproposalsSee omnystudio.com/listener for privacy information.

Show Notes: Martin VanTrieste, President &amp; Chief Executive Officer, Civica - Martin VanTrieste brings over 35 years in the pharmaceutical industry – focusing on manufacturing and quality. He was ranked #2 on the 2018 Medicine Maker Power List of Industry Influencers. Martin VanTrieste was the Chairman of the Parenteral Drug Association (PDA) Board of Directors. The PDA represents over 10,000 members, and is the leading global facilitator of scientifically sound, practical technical information, quality systems and expertise to advance Pharmaceutical / biopharmaceutical manufacturing science and regulation so members can better serve patients. He recently retired as the senior vice president of quality at Amgen. He was responsible for quality assurance, quality control, compliance, operational excellence, environment, health and safety along with training at Amgen. Prior to joining Amgen, VanTrieste was with Bayer Healthcare’s Biological ProductsDivision as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division. While at Abbott, VanTrieste held various positions in Quality, Operations, and Research and Development. He started his career at Abbott in 1983 after obtaining his Pharmacy degree from Temple University School of Pharmacy. He is the founder of Rx-360 and first Chairman of the Board of Directors. Rx-360 is a nonprofit international supply chain organization that enhances patient safety by increasing the security and quality in the biopharmaceutical supply chain. VanTrieste has been actively involved with various professional and trade organizations, including, United States Pharmacopeia (USP), Pharmaceutical Quality Research Institute (PQRI), Pharmaceutical Research and Manufactures of America (PhRMA), and AdvaMed. PharmaVoice in 2012 named VanTrieste as one of the 100 most inspiring people inthe pharmaceutical industry, calling him “a man with a mission”. The MedicineMaker in 2016, 2017 and 2018 named him one of the most influential people in the world of drug development and manufacture saying, “he is known throughoutindustry for his work on advancing quality assurance and helping to ensure a more reliable supply of high-quality medicines.”    Civica Webpage: <a href="https://civicarx.org/" rel="nofollow" target="_blank">https://civicarx.org/</a>    ASCP's call for proposals page - share your expertise with our members in 2019!  <a href="https://www.ascp.com/page/callforproposals" rel="nofollow" target="_blank">https://www.ascp.com/page/callforproposals</a>See <a href="https://omnystudio.com/listener" rel="nofollow" target="_blank">omnystudio.com/listener</a> for privacy information.